Experience unparalleled lab performance with the Ortho VITROS® XT Systems. Designed to minimize errors and reduce the need for repeat testing, these integrated clinical chemistry and immunoassay analyzers deliver a market-leading first pass yield of 96.5%. With waterless operation, the system cuts down on both costs and waste disposal, while its low sample volume requirement (as little as 2 µL per test) makes it ideal for conserving precious samples. Enjoy up to 25% faster turnaround times for routine test panels and next-generation throughput—up to 40% higher with the new XT analyzers. The advanced Digital Chemistry™ platform, featuring a digital reflectometer and innovative XT MicroSlides, ensures that results are both precise and reliable. Plus, with a comprehensive assay menu that includes critical tests like SARS‑CoV‑2 antibodies, HIV combo, procalcitonin, and more, you can future‑proof your lab for growing testing demands.
Key Points:
- High First Pass Yield: Achieves 96.5% first pass yield to minimize repeat testing.
- Waterless Operation: No need for water, lowering costs and environmental impact.
- Fast Turnaround: Up to 25% faster TAT for common test panels.
- Low Sample Volume: Requires only 2–80 µL per test.
- Enhanced Throughput: Next‑gen XT analyzers deliver up to 40% higher throughput.
- Comprehensive Assay Menu: Supports a wide range of critical assays, including SARS‑CoV‑2, HIV, and procalcitonin.
- Digital Chemistry™: Incorporates advanced digital reflectometer and XT MicroSlides for improved accuracy.
- Integrated Informatics: Streamlines workflow with robust automation and connectivity.
Reviews
There are no reviews yet.